| granisetron oral / Generic mfg. |
| Completed | 1 | 80 | Canada | Granisetron hydrochloride 1 mg tablets, Kytril® 1 mg tablets | Teva Pharmaceuticals USA | Healthy | 07/05 | 07/05 | | |
NCT00834717: Granisetron 1 mg Tablets Under Fasting Conditions |
|
|
| Completed | 1 | 40 | Canada | Granisetron hydrochloride 1 mg tablets, Kytril® 1 mg tablets | Teva Pharmaceuticals USA | Healthy | 09/05 | 09/05 | | |
NCT00511823: The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects |
|
|
| Completed | 1 | 16 | US | casopitant, dolasetron, granisetron, rosiglitazone | GlaxoSmithKline | Nausea and Vomiting, Chemotherapy-Induced | 09/07 | 09/07 | | |
NCT02563951: Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers |
|
|
| Completed | 1 | 50 | RoW | GNS Spray 0.5mg, Granisetron Nasal Spray, GNS Spray 1.0mg, GNS Spray 2.0mg, Kytril 1mg (IV injection), Granisetron, Kytril 1mg (Tablet) | Maxinase Life Sciences Ltd., Tri-Service General Hospital | Cancer | 12/15 | 12/15 | | |
NCT03333824: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer |
|
|
| Completed | 1 | 33 | US | CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775 | AstraZeneca, Quintiles, Inc. | Solid Tumours | 01/19 | 01/19 | | |
